ArticleFrontiers in immunology2025
Hashimoto's thyroiditis is associated with reduced invasiveness in papillary thyroid carcinoma: a propensity score-matched retrospective cohort study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive value of conventional ultrasonographic features combined with clinical factors for capsular invasion in papillary thyroid carcinoma with Hashimoto's thyroiditis.American journal of cancer research · 2026Article
- Dual nomograms to predict central and lateral cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: a two-cohort study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid cancer (PTC), the predominant histologic subtype of thyroid cancer cases, has increased substantially over the past decades. In previous studies, Hashimoto's thyroiditis (HT) exerts a paradoxical dual role in PTC. However, limited studies have specifically examined the association between HT and the invasion of PTC. Methods: In this retrospective study, 10329 PTC patients were selected, and the clinicopathological features were retrospectively analyzed. Propensity score matching (PSM) was employed to minimize confounding effects from baseline variables. Univariate analysis and multivariate analysis were performed using binary logistic regression to determine the predictive factor. Odds ratio (OR) and 95% confidence interval (CI) were calculated. Results: Among 10329 PTC patients, 992 (9.6%) individuals were diagnosed with HT. Compared to the non-HT group, the HT group demonstrated lower rates of extrathyroidal extension (p<0.001), reduced multifocality (p=0.004), decreased bilateral carcinoma involvement (p<0.001), and a greater proportion of pathological N0 stage tumors (p=0.003). Following PSM, a cohort of 970 patients with HT and 2783 non-HT controls without HT were analyzed. HT was significantly associated with lower rates of: central lymph node metastasis (CLNM) in cN0 patients (p<0.001); lateral lymph node metastasis (LLNM) in cN1b patients (p=0.008); and bilateral carcinoma detection in patients with clinically unilateral PTC lesions (p=0.001). Conclusion: This study found an association between HT and reduced invasiveness of PTC, as evidenced by increased node-negative disease and reduced bilateral pathological involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.